Plain-English translation of NCT07028970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This is a long-term follow-up study for patients who have received Equecabtagene Autoleucel Injection, a type of CAR-T cell therapy designed to treat multiple myeloma. Researchers want to track how well this medication continues to work over time and watch carefully for any long-term side effects. Since this therapy involves modifying your own immune cells, doctors need to monitor patients for at least 15 years to ensure lasting safety and effectiveness.
Gene therapy products like this medication can have long-term effects that take years to fully understand. By following patients over many years, researchers can identify any delayed safety concerns and confirm that the treatment continues to help patients, which helps doctors decide whether this therapy is truly worth its risks and benefits.
You likely qualify if…
You likely don't qualify if…
You will be asked to return for regular check-ins and monitoring visits over a long period (at least 15 years). During these visits, your doctors will check your health status, monitor how well the treatment is working, run blood tests to track whether the CAR-T cells are still present in your body, and watch for any delayed side effects. This is primarily a monitoring and data-collection study rather than receiving new treatment.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China